DBV Technologies S.A.
NASDAQ:DBVTBiotechnology
-$0.16 today
- Market cap
- $238.98M
- Beta
- -0.22
- P/E (TTM)
- -8.3
- EPS (TTM)
- -$0.39
Volume 0.17M
Average 0.24M
DBVT Total Liabilities
Everything the company owes to creditors and other parties.
DBV Technologies S.A.NASDAQ: DBVT
Total Liabilities · Q1 FY2026 · quarter ended Mar 2026
Total liabilities rises 22.7% from a year ago
Total liabilities stood at $58.5M at the end of Q1 FY2026, up 22.7% from a year earlier and down 9.9% from the prior quarter. Over 3 fiscal years it compounded at +7.6% a year.
Context
- Total liabilities amounted to 22.0% of total assets at the end of Q1 FY2026, down 72.4 pp from a year earlier.
- Total liabilities increased in 1 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether total liabilities keeps rising in the next quarterly balance sheet after a +22.7% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Total Liabilities history
USD · from the balance sheet
- Latest · FY2025
- 64.95M USD
- Year-over-year change
- +69.7%
- 4-year CAGR
- +8.3%
| Period | Period end | Total Liabilities | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 64.95M | +69.7% |
| FY2024 | 2024-12-31 | 38.27M | -10.6% |
| FY2023 | 2023-12-31 | 42.8M | -17.8% |
| FY2022 | 2022-12-31 | 52.07M | +10.1% |
| FY2021 | 2021-12-31 | 47.29M | — |
Total Liabilities vs competitors
How DBVT compares with its peers on the latest reported figures
- DBVT's Mar 2026 total liabilities of $58.5M is the 4th highest of the 11 companies compared; the peer median is $52M.
- Its year-over-year change of +22.7% is the 5th highest of 11, against a peer median of +4.5%.
- Total liabilities amounts to 22.0% of total assets for DBVT, versus a peer median of 19.6%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Mar 2026 | $229.27M | -7.5% | +22.5% | 79.3% | |
| Mar 2026 | $196.35M | +7.9% | -10.1% | 30.4% | |
| Mar 2026 | $63.99M | +1.2% | -28.9% | 34.8% | |
| Mar 2026 | $58.5M | +22.7% | +7.6% | 22.0% | |
| Mar 2026 | $58.36M | -1.5% | +6.9% | 22.2% | |
ENGNenGene Holdings Inc. | Apr 2026 | $52.36M | +33.0% | +126.6% | 17.0% |
| Mar 2026 | $51.64M | +242.0% | +36.5% | 15.4% | |
| Mar 2026 | $50.48M | +94.9% | +63.5% | 24.2% | |
| Mar 2026 | $32.89M | +0.2% | -27.8% | 11.9% | |
LXEOLexeo Therapeutics, Inc. Common Stock | Mar 2026 | $18.86M | -49.8% | -52.8% | 7.5% |
LBRXLB Pharmaceuticals Inc Common Stock | Mar 2026 | $14.79M | +66.9% | -38.6% | 3.8% |
| Peer median (excluding DBVT) | $52M | +4.5% | -1.6% | 19.6% | |
Competitors are the stored peer set for DBVT. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Cash & Equivalents | 77.3M | 209.19M | 141.37M | 32.46M | 194.17M |
| Short-term Investments | 0 | 0 | 0 | 0 | 0 |
| Net Receivables | 33.07M | 10.49M | 15.45M | 10.39M | 16.15M |
| Inventory | 0 | 2.68M | 0 | 0 | 0 |
| Other Current Assets | 0 | 1K | 0 | 0 | 0 |
| Total Current Assets | 114.52M | 223.07M | 158.92M | 44.39M | 212.94M |
| Property, Plant & Equipment (Net) | 24.92M | 17.61M | 17.93M | 16.81M | 14.95M |
| Goodwill | 0 | 661 | 0 | 0 | 0 |
| Intangible Assets | 22K | 9.34K | 58K | 40K | 22K |
| Long-term Investments | 3.97M | 1.66M | 3.68M | 4.31M | 620K |
| Tax Assets | 0 | (1.66M) | 0 | 0 | 0 |
| Other Non-current Assets | 2.9M | 5.83M | 2.4M | 111K | 5.19M |
| Total Non-current Assets | 31.81M | 23.44M | 24.07M | 21.27M | 20.78M |
| Total Assets | 146.32M | 246.52M | 182.99M | 65.66M | 233.72M |
| Account Payables | 11.43M | 14.47M | 23.3M | 22.03M | 40.94M |
| Short-term Debt | 3.51M | 1.13M | 883K | 846K | 16.27M |
| Tax Payables | 182K | 69K | 201.87K | 188K | 0 |
| Deferred Revenue | 4.15M | 2.14M | 0 | 0 | 0 |
| Other Current Liabilities | 12.13M | 9.82M | 11.79M | 7.42M | 217K |
| Total Current Liabilities | 31.4M | 29.52M | 37.34M | 31.14M | 58.03M |
| Long-term Debt | 0 | 0 | 0 | 0 | 0 |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue (Non-current) | 0 | 0 | 0 | 0 | 0 |
| Other Non-current Liabilities | 8.75M | 21.42M | 934K | 838K | 1.51M |
| Total Non-current Liabilities | 15.9M | 22.54M | 5.46M | 7.14M | 6.92M |
| Total Liabilities | 47.29M | 52.07M | 42.8M | 38.27M | 64.95M |
| Common Stock | 6.54M | 10.72M | 10.97M | 11.65M | 26.08M |
| Retained Earnings | (98.05M) | (259.58M) | (238.86M) | (286.38M) | (393.13M) |
| Accumulated OCI | (15.4M) | (13.8M) | (8.13M) | (12.19M) | (5.43M) |
| Other Stockholders Equity | 6.14M | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 |
| Total Equity | 99.03M | 194.45M | 140.19M | 27.39M | 168.77M |
| Total Debt | 10.66M | 4.15M | 6.55M | 7.8M | 21.68M |
| Net Debt | (66.64M) | (205.04M) | (134.81M) | (24.66M) | (172.48M) |
DBV Technologies S.A.
NASDAQ:DBVT
Intrinsic Alpha fair value
Locked
Current Price
$9.99
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.